Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Non-radiographic Axial Spondyloarthritis (nr-axSpA) Maintenance of Remission
NCT05622708Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2023
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 4 trial of secukinumab in non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by Novartis. Started Mar 2023; status: active, not recruiting.
02
Drugs
secukinumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NCT05622708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05622708.